About
PhoreMost is a Cambridge UK-based biotechnology company dedicated to turning scientific breakthroughs into life-changing cancer therapies. The company's lead program, PMC-001, is a differentiated orally bioavailable, CNS-penetrant microtubule disruptor positioned to treat primary and metastatic brain cancers. The company is advancing PMC-001 to Phase 1/2a clinical evaluation in addition to progressing pipeline assets in Discovery.
Pipeline
PhoreMost is developing its pipeline of small molecule drugs, targeting cancers of high unmet clinical need
| Programme | Modality | Indication | Feasability | Discovery | Pre-Clinical | Phase 1 |
|---|---|---|---|---|---|---|
| PMC-001 | Small molecule | Primary and Secondary Brain Cancers | ||||
| PMC-002 | Small molecule | HPV+ Cancers | ||||
| PMC-003 | Bifunctional degrader | Oncology | ||||
Scroll / Drag to view
Partnering Opportunities
In addition to the programmes above, PhoreMost is also using its proprietary chemistry against multiple novel E3 ligases to develop next-generation targeted protein degradation therapeutics.
News
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies
5th January 2022
PhoreMost closes £33M ($46M) Series B financing
23rd March 2021
Contact us
We are interested in hearing from potential collaborators and employees from all pursuits to join with us in developing new therapies to unmet diseases.
+44 (0)1223 856 740
Moneta Building, B280, Babraham Research Campus, Cambridge, CB22 3AT